New clinical investigations have shed light on the safety and effectiveness of infliximab biosimilar CT-P13 in rheumatic diseases and demonstrated interchangeability between CT-P17 and reference adalimumab for chronic plaque psoriasis. These phase 3 studies address critical questions regarding biosimilar adoption, tolerability, and therapeutic switching in autoimmune conditions, offering insights poised to influence treatment guidelines and payer policies.